Sponsored by THOR Photomedicine
This activity is not certified for credit.
Date
Thursday, September 9
Start Time
10:30a
End Time
11:20a
Room
Castellana
Level 3
Program Description
Photobiomodulation (PBM) is an FDA cleared alternative to opioid pain relief using red and near-infrared non-thermal lasers and light-emitting diodes.
PBM, when applied to pathologies, is absorbed in mitochondria reducing the underlying cause of oxidative stress and increasing ATP. Downstream effects act on NF-κβ to reduce inflammatory cytokines and increase tissue regenerative transcription factors.
PBM is already standard of care in many institutions and is recommended to the National Health Service (NHS) by the UK National Institute for Health and Care Excellence (NICE). PBM is also recommended by the Multinational Association for Supportive Care in Cancer (MASCC) for the treatment of oral mucositis, a painful inflammatory and ulcerative condition caused by high-dose chemotherapy or radiotherapy.
Over 800 RCTs have demonstrated that PBM is a safe and effective treatment for a wide range of painful pathologies including, post-operative pain, Oral Mucositis, posthepatic neuralgia, osteoarthritis of the knee, back and neck pain.
Systematic reviews published by the WHO, Lancet, BMJ, BJSM often report “strong evidence” for PBMs efficacy and THOR products have delivered more than 30 Million treatments with no adverse events.
The presentation will review results from RCTs showing reduced use of opioids in active PBM treated patients versus placebo controls.
LEARNING OBJECTIVES
Photobiomodulation mechanisms of action
Photobiomodulation range of clinical applications
Photobiomodulation dose response
Faculty
James Carroll
Pre-event Registration
No preregistration required
Refreshments will be served
Contact Name
Mark Granic
Contact Phone
(877) 355-3151
Contact email
[email protected]